Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Honeywell International Inc (HON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Honeywell International Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Honeywell International Inc trades at $222.13 (market cap $71.30B). The key difference: Honeywell International Inc is far larger — about 15.9× ACADIA Pharmaceuticals Inc.'s market cap, and Honeywell International Inc pays a 4.23% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HON | |
|---|---|---|
Market Cap | $4.49B | $71.30B |
Sector | Health | Industrials |
52-Week High | $28.06 | $248.04 |
52-Week Low | $20.06 | $188.14 |
Enterprise Value | $3.69B | $95.65B |
Dividend Yield | — | 4.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Honeywell Technologies (HON) trades at $225.05, down 2.09% today, following the completion of its aerospace spinoff on June 29, 2026. The stock shows strong fundamentals with a P/E of 18.46 and consistent earnings beats in recent quarters. Technical indicators suggest a bullish trend with support at $225 and resistance at $234. The company maintains solid profitability with 10.89% net margins and 26.41% ROE, though revenue declined slightly to $37.44B in 2025.
The outlook remains positive with 64% analyst buy ratings and a $402.40 consensus price target, representing 79% upside potential. Key risks include integration challenges from recent spinoffs and rising debt-to-asset ratio (46.65% in 2025). The company's focus on high-growth automation segments and ESG alignment provides long-term growth catalysts, though near-term volatility may persist during the post-spinoff transition period.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
